Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas.

The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in BagsvŠrd, Denmark.

Number of employees : 40 638 persons.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care69,98078.8%85,59079.3% +22.31%
Biopharmaceuticals18,82621.2%22,33720.7% +18.65%
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
North America43,12348.6%56,85752.7% +31.85%
Europe20,15022.7%20,79819.3% +3.22%
International12,54014.1%14,96613.9% +19.35%
China8,0889.1%9,8719.1% +22.05%
Japan & Korea4,9055.5%5,4355% +10.81%
Managers
NameAgeSinceTitle
Lars Rebien S°rensen621982President & Chief Executive Officer
G÷ran Ando672005Chairman
Jesper Brandgaard, MBA531999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD561991Chief Science Officer & Executive Vice President
Mads Krogsgaard--Chief Science Officer
Anne Marie Handrup Kverneland601981Director
Stig Str°bŠk521992Director
Bruno Francois Jules Angelici, MBA692011Independent Non-Executive Director
Elizabeth Anne Hewitt602012Independent Director
S°ren Thuesen Pedersen, MBA521994Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,112,564,000 1,796,581,297 85.0% 52,168,703 2.5% 67.8%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.14%
Capital Research & Management Co. (World Investors) 147,662,860 7.34%
Novo Nordisk A/S 39,901,083 1.98%
The Vanguard Group, Inc. 37,833,358 1.88%
Norges Bank Investment Management 36,416,979 1.81%
Carmignac Gestion SA 27,869,686 1.38%
Northern Cross LLC 27,431,187 1.36%
BlackRock Investment Management (UK) Ltd. 21,282,682 1.06%
Alecta Pension Insurance Mutual 20,908,000 1.04%
BlackRock Fund Advisors 16,647,857 0.83%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 39,901,0831.98%1,425,259,104 USD
Nnit A/S (NNIT) 6,375,00025.5%189,291,791 USD
Innate Pharma (IPH) 5,422,70810.1%63,604,786 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S-39.23%70 980
JOHNSON & JOHNSON8.05%302 251
ROCHE HOLDING LTD.-19.97%190 015
PFIZER INC.-3.38%189 272
NOVARTIS AG-20.79%178 826
MERCK & CO., INC.13.82%165 594
SANOFI-4.45%104 494
BRISTOL-MYERS SQUIBB C..-19.71%92 319
GLAXOSMITHKLINE PLC6.52%90 565
BAYER AG-24.74%80 400
ELI LILLY AND CO-20.26%74 384
ALLERGAN PLC-39.69%71 164
ASTRAZENECA PLC-12.54%64 251
ABBOTT LABORATORIES-13.87%56 654
SHIRE PLC-7.82%49 924
TAKEDA PHARMACEUTICAL ..-23.75%32 063
ASTELLAS PHARMA INC-11.15%29 042
MYLAN NV-36.19%18 461
EISAI CO., LTD-20.70%16 701
JIANGSU HENGRUI MEDICI..-80.53%16 325
SHIONOGI & CO LTD-9.57%16 017
Sector Pharmaceuticals - NEC
Novo Nordisk A/S : Connections
Novo Nordisk A/S
Novo AllÚ
BagsvŠrd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
© 2016 People , Fundamentals and Ownership